139 related articles for article (PubMed ID: 33468348)
21. [Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy].
Kurenkov AL; Klochkova OA; Bursagova BI; Karimova HM; Kuzenkova LM; Mamedyarov AM; Namazova-Baranova LS; Agranovich OV; Agranovich AO; Soboleva OA; Khapaeva MM; Batysheva TT; Sarzhina MN
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):37-44. PubMed ID: 29265085
[TBL] [Abstract][Full Text] [Related]
22. The influence of physical therapy and anti-botulinum toxin antibody on the efficacy of botulinum toxin-A injections in children with spastic cerebral palsy.
Jang DH; Sung IY
Dev Neurorehabil; 2014 Dec; 17(6):414-9. PubMed ID: 25372070
[TBL] [Abstract][Full Text] [Related]
23. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
Yang TF; Fu CP; Kao NT; Chan RC; Chen SJ
Am J Phys Med Rehabil; 2003 Apr; 82(4):284-9. PubMed ID: 12649654
[TBL] [Abstract][Full Text] [Related]
24. Development of an inventory of goals using the International Classification of Functioning, Disability and Health in a population of non-ambulatory children and adolescents with cerebral palsy treated with botulinum toxin A.
Nguyen L; Mesterman R; Gorter JW
BMC Pediatr; 2018 Jan; 18(1):1. PubMed ID: 29301539
[TBL] [Abstract][Full Text] [Related]
25. Botulinum Toxin Type A injections for pediatric spasticity: Keeping our patients informed and practices safe.
Wright E; Fetsko L
J Pediatr Rehabil Med; 2021; 14(2):199-211. PubMed ID: 34057107
[TBL] [Abstract][Full Text] [Related]
26. [Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience].
Kurenkov AL; Kuzenkova LM; Bursagova BI; Klochkova OA; Chernikov VV; Kuznetsova MA; Ashrafova US; Kuprianova OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7):68-77. PubMed ID: 32790979
[TBL] [Abstract][Full Text] [Related]
27. [High doses of botulinum toxin type A in children: efficacy and safety in clinical practice].
Filipetti P; Chantraine F
Ann Readapt Med Phys; 2007 Jan; 50 Suppl 1():S7-S11. PubMed ID: 17550812
[TBL] [Abstract][Full Text] [Related]
28. A risk-stratified approach toward safely resuming OnabotulinumtoxinA injections based on dosing and ambulatory status in pediatric patients with cerebral palsy during the Coronavirus pandemic of 2019 (COVID-19).
McLaughlin MJ; Fisher MT; Vadivelu S; Ramsey J; Ratnasingam D; McGhee E; Hartman K
J Pediatr Rehabil Med; 2020; 13(3):273-279. PubMed ID: 33252098
[TBL] [Abstract][Full Text] [Related]
29. Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy.
Büyükavcı R; Büyükavcı MA
Acta Neurol Belg; 2018 Sep; 118(3):429-433. PubMed ID: 29694645
[TBL] [Abstract][Full Text] [Related]
30. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.
Naidu K; Smith K; Sheedy M; Adair B; Yu X; Graham HK
Dev Med Child Neurol; 2010 Feb; 52(2):139-44. PubMed ID: 20412252
[TBL] [Abstract][Full Text] [Related]
31. Safety profile of incobotulinum toxin A [Xeomin(®)] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial.
Carraro E; Trevisi E; Martinuzzi A
Eur J Paediatr Neurol; 2016 Jul; 20(4):532-7. PubMed ID: 27177451
[TBL] [Abstract][Full Text] [Related]
32. A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE.
Chaléat-Valayer E; Parratte B; Colin C; Denis A; Oudin S; Bérard C; Bernard JC; Bourg V; Deleplanque B; Dulieu I; Evrard P; Filipetti P; Flurin V; Gallien P; Héron-Long B; Hodgkinson I; Husson I; Jaisson-Hot I; Maupas E; Meurin F; Monnier G; Pérennou D; Pialoux B; Quentin V; Moreau MS; Schneider M; Yelnik A; Marque P
Eur J Paediatr Neurol; 2011 Sep; 15(5):439-48. PubMed ID: 21745754
[TBL] [Abstract][Full Text] [Related]
33. Botulinum Toxin: Techniques Within Pediatric Physiatry.
Paulson A; Zigler CK; Houtrow A; Pruitt D
PM R; 2019 Jan; 11(1):38-44. PubMed ID: 29964211
[TBL] [Abstract][Full Text] [Related]
34. Changes in Muscle Mass after Botulinum Toxin Injection in Children with Spastic Hemiplegic Cerebral Palsy.
Lee D; Kim J; Oh JY; Han MH; Kim DY; Kang JH; Jang DH
Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33919735
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal assessment of gait quality in children with bilateral cerebral palsy following repeated lower limb intramuscular Botulinum toxin-A injections.
Read FA; Boyd RN; Barber LA
Res Dev Disabil; 2017 Sep; 68():35-41. PubMed ID: 28735160
[TBL] [Abstract][Full Text] [Related]
36. Effects of botulinum toxin serotype A on sleep problems in children with cerebral palsy and on mothers sleep quality and depression.
Binay Safer V; Ozbudak Demir S; Ozkan E; Demircioglu Guneri F
Neurosciences (Riyadh); 2016 Oct; 21(4):331-337. PubMed ID: 27744462
[TBL] [Abstract][Full Text] [Related]
37. Comparison of bispectral index values and depth of sedation during deep sedation using sevoflurane anesthesia in healthy children versus children with cerebral palsy.
Onal P; Oztas N; Kip G
Niger J Clin Pract; 2019 Jun; 22(6):801-805. PubMed ID: 31187765
[TBL] [Abstract][Full Text] [Related]
38. Development of treatment concepts for the use of botulinum toxin a in children with cerebral palsy.
Placzek R; Siebold D; Funk JF
Toxins (Basel); 2010 Sep; 2(9):2258-71. PubMed ID: 22069684
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy.
Lundy CT; Doherty GM; Fairhurst CB
Dev Med Child Neurol; 2009 Sep; 51(9):705-10. PubMed ID: 19459910
[TBL] [Abstract][Full Text] [Related]
40. A pragmatic approach to Botulinum Toxin safety.
Vova JA; Leung E
J Pediatr Rehabil Med; 2020; 13(2):195-199. PubMed ID: 32568125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
